Balyasny Asset Management
DYN icon

Balyasny Asset Management’s Dyne Therapeutics DYN Stock Holding History

Balyasny Asset Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-432,986
Closed -$8.47M – 3037
2025
Q4 		$8.47M Buy
+432,986
New +$8.2M 0.01% 1110
2025
Q3 		– Sell
-488,498
Closed -$4.65M – 3027
2025
Q2 		$4.65M Buy
+488,498
New +$5.38M 0.01% 1326
2025
Q1 		– Sell
-169,306
Closed -$3.99M – 2900
2024
Q4 		$3.99M Sell
169,306
-75,804
-31% -$2.24M 0.01% 1379
2024
Q3 		$8.8M Buy
+245,110
New +$9.76M 0.01% 1015
2023
Q4 		– Sell
-17,646
Closed -$158K – 2577
2023
Q3 		$158K Buy
+17,646
New +$190K ﹤0.01% 2069
2022
Q3 		– Sell
-98,866
Closed -$679K – 2930
2022
Q2 		$679K Buy
+98,866
New +$681K ﹤0.01% 1893
2021
Q3 		– Sell
-195,052
Closed -$4.1M – 2057
2021
Q2 		$4.1M Buy
+195,052
New +$3.67M 0.02% 778

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Balyasny Asset Management's DYN Position: Q1 2026 in Review

Balyasny Asset Management sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 432,986 shares — an estimated $8.47M sold.

Balyasny Asset Management first reported a position in DYN in Q2 2021 and held it in 7 quarters. The position peaked at $8.8M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Balyasny Asset Management reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 432,986 Dyne Therapeutics shares in Q1 2026, an estimated $8.47M.
  • Balyasny Asset Management first reported a position in Dyne Therapeutics in Q2 2021 and held it in 7 quarters.
  • Balyasny Asset Management's Dyne Therapeutics position peaked at $8.8M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.